InvestorsHub Logo
Post# of 26891
Next 10
Followers 437
Posts 42954
Boards Moderated 2
Alias Born 05/08/2006

Re: None

Tuesday, 10/17/2017 10:01:48 AM

Tuesday, October 17, 2017 10:01:48 AM

Post# of 26891
Compensated Awareness Post View Disclaimer
QualityStocksNewsBreaks – ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) Names Paul Lucas as New Board Chair

ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) this morning announced its appointment of Paul Lucas as its new independent chair following founder Ken Clement’s decision to step down from the position. Clement will continue to serve as a member of the company’s board of directors. “Ken’s visionary leadership has given ABcann a great foundation to build upon and we appreciate his years of dedicated service and contributions,” Paul Lucas stated in the news release. “Having him maintain his position on the Board will help the Company maintain continuity of leadership and historical knowledge. I am thrilled to take on the Chair position as we enter the next phase in our evolution.” Lucas brings decades of pharmaceutical industry experience to the ABcann board, having previously served as president and CEO of GlaxoSmithKline Canada from 1994 to 2012. This morning’s update follows last month’s appointment of Barry Fishman as the company’s new CEO. ABcann notes that, together, these appointments “represent important steps in the Company’s enhancement of its operational oversight and corporate governance standards.”

To view the full press release, visit http://dtn.fm/h922O

About ABcann Global Corporation

ABcann, which holds production and sales licenses from Health Canada, is based in Napanee, Ontario. Its flagship facility contains proprietary plant-growing technology, centred on its specially designed, environmentally-controlled growing chambers. This approach and the systems in place allow ABcann to produce organically grown and pesticide-free, high-yielding plants, which, in turn, can generate high-quality products. ABcann is able to control environmental and nutrient demands, tailor-made for a particular strain of cannabis, without the variation that is typical when producing large quantities in less-controlled, larger rooms and greenhouse-type structures. ABcann’s modular approach to systems technology eliminates scale-up risk and enables ABcann to expand anywhere in the world and maintain consistency and quality of product.

ABcann is expanding capacity in its current facility to approximately 30,000 sq ft and concurrently undertaking its expansion into a new 150,000 sq ft facility in Napanee. ABcann is pursuing opportunities in Germany, Australia, Israel and other jurisdictions as well as exploring the development of multiple delivery vehicles.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.